Search results
Showing 76 to 90 of 182 results for pembrolizumab
Cancer of the upper aerodigestive tract: assessment and management in people aged 16 or over (NG36)
This guideline covers assessing and managing cancers of the upper aerodigestive tract in people aged 16 or over. These are cancers of the airways of the head and neck, including the mouth, throat, larynx (voicebox) and sinuses. The guideline aims to reduce variation in practice and improve survival.
Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [TSID10690]
Awaiting development Reference number: GID-TA11073 Expected publication date: TBC
Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.
Show all sections
This guideline covers diagnosing and managing bladder cancer in people 18 and above referred from primary care with suspected bladder cancer, and those with newly diagnosed or recurrent bladder (urothelial carcinoma, adenocarcinoma, squamous-cell carcinoma or small-cell carcinoma) or urethral cancer.
Awaiting development Reference number: GID-TA11469 Expected publication date: TBC
This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and secondary tumours (metastatic disease).
Awaiting development Reference number: GID-TA11950 Expected publication date: TBC
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]
Awaiting development Reference number: GID-TA11300 Expected publication date: TBC
Awaiting development Reference number: GID-TA11724 Expected publication date: TBC
Pembrolizumab for previously treated multiple myeloma (ID1139)
Discontinued Reference number: GID-TA10193
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]
Discontinued Reference number: GID-TA10244
Awaiting development Reference number: GID-TA11202 Expected publication date: TBC
Awaiting development Reference number: GID-TA11751 Expected publication date: TBC
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
Discontinued Reference number: GID-TA10418
Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]
Discontinued Reference number: GID-TA10380